D-Chicoric AcidCAS# 52248-48-3 |
- Chicoric acid
Catalog No.:BCN1215
CAS No.:70831-56-0
- Cichoric acid
Catalog No.:BCN9033
CAS No.:6537-80-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 52248-48-3 | SDF | Download SDF |
| PubChem ID | 5470299 | Appearance | Powder |
| Formula | C22H18O12 | M.Wt | 474.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | D-DCTA; Dicaffeoyl-D-Tartaric Acid | ||
| Solubility | DMSO : ≥ 347 mg/mL (731.50 mM); | ||
| Chemical Name | (2S,3S)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid | ||
| SMILES | C1=CC(=C(C=C1C=CC(=O)OC(C(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)C(=O)O)O)O | ||
| Standard InChIKey | YDDGKXBLOXEEMN-QFZCZCNSSA-N | ||
| Standard InChI | InChI=1S/C22H18O12/c23-13-5-1-11(9-15(13)25)3-7-17(27)33-19(21(29)30)20(22(31)32)34-18(28)8-4-12-2-6-14(24)16(26)10-12/h1-10,19-20,23-26H,(H,29,30)(H,31,32)/b7-3+,8-4+/t19-,20-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
D-Chicoric Acid Dilution Calculator
D-Chicoric Acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1079 mL | 10.5396 mL | 21.0793 mL | 42.1585 mL | 52.6981 mL |
| 5 mM | 0.4216 mL | 2.1079 mL | 4.2159 mL | 8.4317 mL | 10.5396 mL |
| 10 mM | 0.2108 mL | 1.054 mL | 2.1079 mL | 4.2159 mL | 5.2698 mL |
| 50 mM | 0.0422 mL | 0.2108 mL | 0.4216 mL | 0.8432 mL | 1.054 mL |
| 100 mM | 0.0211 mL | 0.1054 mL | 0.2108 mL | 0.4216 mL | 0.527 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cichoric Acid, a natural product, is reported to be antioxidative.
References:
[1]. Line Thygesen, et al. Antioxidant activity of cichoric acid and alkamides from Echinacea purpurea, alone and in combination. Food Chemistry
Volume 101, Issue 1, 2007, Pages 74–81
[2]. Qu L, et al. Patterns of Variation in Alkamides and Cichoric Acid in Roots and Aboveground Parts of Echinacea purpurea (L.) Moench. HortScience. 2005 Aug;40(5):1239-1242.
- H-D-Pro-OMe.HCl
Catalog No.:BCC3025
CAS No.:65365-28-8
- 2,6-Tropanediol
Catalog No.:BCN1875
CAS No.:65356-02-7
- Demethylvestitol
Catalog No.:BCN4079
CAS No.:65332-45-8
- Scopolamine hydrobromide trihydrate
Catalog No.:BCC8188
CAS No.:6533-68-2
- L-Norgestrel
Catalog No.:BCC9105
CAS No.:797-64-8
- Primulic Acid 1
Catalog No.:BCC8236
CAS No.:65312-86-9
- Calhex 231 hydrochloride
Catalog No.:BCC7931
CAS No.:652973-93-8
- Ketoconazole
Catalog No.:BCC2272
CAS No.:65277-42-1
- Arvenin II
Catalog No.:BCN7878
CAS No.:65247-28-1
- Cucurbitacin B 2-O-beta-D-glucoside
Catalog No.:BCN3119
CAS No.:65247-27-0
- Dehydrocrenatidine
Catalog No.:BCN4196
CAS No.:65236-62-6
- N-Glyceryltaurine
Catalog No.:BCN1753
CAS No.:65222-42-6
- alpha-Isowighteone
Catalog No.:BCN4197
CAS No.:65388-03-6
- Bestatin hydrochloride
Catalog No.:BCC3908
CAS No.:65391-42-6
- Morin hydrate
Catalog No.:BCC8214
CAS No.:654055-01-3
- Altholactone
Catalog No.:BCN4786
CAS No.:65408-91-5
- H-D-Asp-Ome
Catalog No.:BCC2896
CAS No.:65414-78-0
- Boc-Asn(Xan)-OH
Catalog No.:BCC3361
CAS No.:65420-40-8
- DL-Dab.2HCl
Catalog No.:BCC2669
CAS No.:65427-54-5
- 1-Methoxyphaseollidin
Catalog No.:BCN7185
CAS No.:65428-13-9
- Phebalosin
Catalog No.:BCN4198
CAS No.:6545-99-9
- Acantrifoic acid A
Catalog No.:BCN6488
CAS No.:654663-85-1
- Fmoc-Asn(Trt)-ol
Catalog No.:BCC2585
CAS No.:654670-89-0
- Sitagliptin phosphate monohydrate
Catalog No.:BCC2111
CAS No.:654671-77-9
Chicoric Acid Improves Heart and Blood Responses to Hypobaric Hypoxia in Tibetan Yaks.[Pubmed:29433395]
Am J Chin Med. 2018;46(2):339-355.
Yak is a wild bovine species living on the Qinghai Tibet Plateau that demonstrates good adaptability to the hypoxic environment. Chicoric acid, a natural phenolic compound, is known as having anti-oxidant, antiviral, anti-inflammatory and analgesic properties. However, its effect on hypoxia adaptability of yak is still unclear. In this study 40 yaks were selected that were of similar age, parity and weight, and divided into the control group and experimental groups 1, 2, 3, randomly. Results showed that chicoric acid significantly improved RBC, HGB, and WBC. There are significantly beneficial effects to increasing total protein contents ([Formula: see text]): all treatments increased HDL-C contents, and supplementations 100[Formula: see text]mg/h significantly decreased the content of TG on the 60th day ([Formula: see text]). Contents of the serum related enzymes like ALP, GOP and GPT showed varying degrees of change, but no significant differences and the indexes of anti-oxidant capacity (T-AOC and GSH-Px) were significantly improved ([Formula: see text]), but MDA was decreased ([Formula: see text]) under the action of the chicoric acid. Hypoxia-inducible factor in serum such as HIF-2[Formula: see text], EPO, ROS, Fe[Formula: see text] and Tf are all significantly decreased ([Formula: see text]). The myocardial mitochondrial parameters mtDNA, UCP2, PGC1-[Formula: see text], NRF1 and mitochondrial complexes were altered remarkably. Some indicators of glucose metabolism presented variation trends. Taken together, chicoric acid has shown a positive effect on the adaptive ability of yak in high altitude, hypoxic environment in plateau areas. Our findings reported a new potential means to enhance immunity and inflammatory response and improve the anti-oxidant capacity.
Role of Chicoric Acid and 13-Cis Retinoic Acid in Mycobacterium tuberculosis Infection Control by Human U937 Macrophage.[Pubmed:29704020]
Arch Immunol Ther Exp (Warsz). 2018 Oct;66(5):399-406.
Mycobacterium tuberculosis (Mtb) survives and proliferates within the main cells of the innate immune system, macrophages. The goal of our study was to investigate the immunostimulatory effects of 13-cis retinoic acid (RA) and chicoric acid (CA) in human U937 macrophages against H37Ra Mtb infection by evaluating its potential role in the cell surface expression of HLA-DR, CD14 molecules as well as nitric oxide (NO) production and prevention of the Mtb growth within macrophages. In this study, we investigated the effects of 13-cis RA and CA on Mtb-infected macrophages using flowcytometry and Griess methods, respectively. Moreover, inhibitory effect of 13-cis RA and CA on Mtb growth within macrophages were assessed using colony-forming unit. 13-Cis RA and CA enhanced the cell surface expression of HLA-DR and CD14 molecules on U937 macrophages and prevented the growth of Mtb within macrophages. In addition, 13-cis RA and CA, have increased NO generation compared to untreated control macrophages, significantly (p < 0.001). Both drugs have a significant inhibitory effect on Mtb growth but CA at the highest concentration was more potent than 13-cis RA (p < 0.05). The results of our study showed that infected U937 macrophages treated with 13-cis RA and CA represented significant increases in NO production, CD14 and HLA-DR expression and also prevents intracellular survival of Mtb. Therefore, 13-cis RA and CA may have a significant therapeutic approach in the control of Mtb infection.
